Cereno Scientific AB (publ) (FRA:4A1)

Market Cap	140.24M -45.8%
Revenue (ttm)	6.09M -11.7%
Net Income	-11.06M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4344
Previous Close	0.4502
Day's Range	0.4344 - 0.4344
52-Week Range	0.4344 - 0.9855
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 11, 2026

About Cereno Scientific AB

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company’s lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thromboti...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 10
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4A1

Financial Performance

In 2025, Cereno Scientific AB's revenue was 44.27 million, a decrease of -45.28% compared to the previous year's 80.90 million. Losses were -117.75 million, 18.3% more than in 2024.

Financial numbers in SEK